Home > Boards > US Listed > Biotechs > Gamida Cell Ltd. (GMDA)

Don't 'Cell' Gamida, Buy It

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 120
Posts 25,376
Boards Moderated 8
Alias Born 02/07/04
160x600 placeholder
Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference Business Wire - 4/7/2021 8:00:00 AM
Gamida Cell Presents Efficacy & Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at th... Business Wire - 3/15/2021 10:24:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/11/2021 4:36:22 PM
Prospectus Filed Pursuant to Rule 424(b)(7) (424b7) Edgar (US Regulatory) - 3/11/2021 4:02:23 PM
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) Edgar (US Regulatory) - 3/11/2021 3:34:31 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 3/11/2021 6:04:18 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/9/2021 4:09:39 PM
Gamida clibs 5.6% despite a Q4 miss, provides 2021 guidance Seeking Alpha - 3/9/2021 11:22:41 AM
Gamida Cell EPS misses by $0.35; outlook Seeking Alpha - 3/9/2021 7:05:01 AM
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update Business Wire - 3/9/2021 7:00:00 AM
Gamida Cell to Present at Upcoming Investor Conferences Business Wire - 3/3/2021 7:00:00 AM
Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast Business Wire - 3/2/2021 7:00:00 AM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 3/1/2021 4:40:43 PM
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Soc... Business Wire - 3/1/2021 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/26/2021 3:13:08 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/17/2021 3:11:52 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/16/2021 2:22:05 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/16/2021 8:58:20 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 8:30:16 AM
Gamida Cell launches $75M financing with Highbridge Capital Management Seeking Alpha - 2/16/2021 8:04:19 AM
Gamida Cell Announces $75 Million Financing with Highbridge Capital Management Business Wire - 2/16/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 5:53:48 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 4:46:15 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2021 3:13:10 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/10/2021 4:02:17 PM
midastouch017   Friday, 01/15/21 09:08:27 AM
Re: None
Post # of 299 
Don't 'Cell' Gamida, Buy It

https://www.thestreet.com/investing/small-cap-stocks-that-could-see-big-gains-in-2021?puc=yahoo&cm_ven=YAHOO

Gamida Cell (GMDA) - Get Report is a biotechnology company that is using cell therapy to address blood cancers and serious blood disorders. Preliminary data has been robust and the company has already indicated that it met three secondary endpoints.

The company expected to report a full peer-reviewed data set in the first half of 2021. It originally intended to apply for a biological license application (BLA) on a rolling basis, but the FDA is requesting details about its planned commercial manufacturing sites.

GMDA2021
Dan Rosenblum, the biotechnology expert at SharkInvesting.com, tells me, “What is really exciting about GMDA is the update on Natural Killer Cell Therapy GDA-201. In an oral presentation at the recent American Society of Hematology (ASH) 62nd Annual Meeting, it was shown that GDA-201 was well tolerated and no dose-limiting toxicities were observed in Phase 1 clinical study. GDA-201 demonstrated significant clinical activity in patients with non-Hodgkin lymphoma, with 13 complete responses and one partial response observed in 19 patients, for a response rate of 74%. ... Basically, the Natural killer cell technology produced cures in three out of four lymphoma patients.”

The company is a long way from final approval in late 2021, but the innovation of cell therapy is already attracting attention and there should be updates on progress in the first half of 2021 to drive the stock. GMDA is currently the largest holding in the ARK Israel Innovative Technology ETF at 247,218 shares.

I will be actively trading these stocks as they develop, but I feel that they have longer-term potential in the year ahead that will help to provide good support.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences